KaydedilenlerDerginizi ekleyin

Dergiler / Medicine Science / 2016 / Cilt: 5 - Sayı: 0

Non-Invasive Prenatal Testing for Aneuploidy: A Review of the Literature

Ayşe KIRBAŞ
Korkut DAĞLAR
Nuri DANIŞMAN
Sayfa
195–209
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this meta-study, we will review the accumulated data on the increasing clinical use of NIPT in perinatology as well as the other presently used conventional noninvasive aneuploidy screening methods.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aneuploidy is one of the leading causes of perinatal deaths and childhood handicaps.
📊
Temel Bulgular & Veri:An important issue that has led to heated debates in the agenda of maternal-fetal medicine and that has been widely investigated in recent years is 'the isolation of fetal deoxyribonucleic acid (DNA) from maternal blood.
💡
Sonuç & Katkı:In this meta-study, we will review the accumulated data on the increasing clinical use of NIPT in perinatology as well as the other presently used conventional noninvasive aneuploidy screening methods.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aneuploidy is one of the leading causes of perinatal deaths and childhood handicaps. An important issue that has led to heated debates in the agenda of maternal-fetal medicine and that has been widely investigated in recent years is 'the isolation of fetal deoxyribonucleic acid (DNA) from maternal blood. It is agreed that fetal DNA can be used in fetal aneuploidy screening and in predicting some pregnancy complications that are considered to be of placenta-based such as preeclampsia and preterm labor. The fetal DNA testing of maternal blood is regarded as an advanced screening test and generally named as 'noninvasive prenatal test' (NIPT). In this meta-study, we will review the accumulated data on the increasing clinical use of NIPT in perinatology as well as the other presently used conventional noninvasive aneuploidy screening methods.

🔖

Bu Makaleye Atıf Yap

KIRBAŞ, A., DAĞLAR, K., DANIŞMAN, N. (2016). Non-Invasive Prenatal Testing for Aneuploidy: A Review of the Literature. Medicine Science, Cilt: 5 - Sayı: 0, 195–209. https://ajindex.com/articles/277892

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15
  2. Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH. Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-Analysis. Fetal Diagn Ther. 2014:41(3):26-32
  3. Ashoor G, Syngelaki A, Poon LCY, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;31(1):237-43
  4. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):322.e1-5
  5. American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109(1):217- 27
  6. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG. 2003;110(3):276-80
  7. Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K. A reassessment of biochemical marker distributions in trisomy 21 affected and unaffected twin pregnancies in the first trimester Ultrasound Obstet Gynecol. 2011;37(1):38-47
  8. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies; a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG. 2000;107(10):1271-5
  9. Spencer K, Ong C, Skentou H, Liao AW, H Nicolaides K. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 2000;20(5):411-6
  10. Spencer K, Tul N, Nicolaides KH. Maternal serum free beta hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn. 2000;20(5):390-4
  11. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J. 1992;304(6831):867-9
  12. Nicolaides KH, Snijders RJM, Gosden RJM, Berry C, Campbell S. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet. 1992;340(8821):704-7
  13. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using feta